CLAIMS

1. A T Cell Immunoglobulin and Mucin Domain-3 (TIM-3) binding agent comprising a light chain CDR1 comprising RASQSIRRYLN (SEQ ID NO: 332); a light chain CDR2 comprising GASTLQS (SEQ ID NO: 333); a light chain CDR3 comprising QQSHSAPLT (SEQ ID NO: 334); a heavy chain CDR1 comprising GFTFSSYDMS (SEQ ID NO: 329); a heavy chain CDR2 comprising TISGGGTYTYYQDSVKG (SEQ ID NO: 330); and a heavy chain CDR3 comprising MDY (SEQ ID NO: 331).

2. The TIM-3 binding agent of claim 1, comprising a light chain variable region (VL) that is at least 90% identical to SEQ ID NO: 115.

3. The TIM-3 binding agent of claim 1, comprising a light chain variable region (VL) that is at least 95% identical to SEQ ID NO: 115.

4. The TIM-3 binding agent of claim 1, comprising a light chain variable region (VL) that is identical to SEQ ID NO: 115.

5. The TIM-3 binding agent of claim 1, comprising a heavy chain variable region (VH) that is at least 90% identical to SEQ ID NO: 34.

6. The TIM-3 binding agent of claim 1, comprising a heavy chain variable region (VH) that is at least 95% identical to SEQ ID NO: 34.

7. The TIM-3 binding agent of claim 1, comprising a heavy chain variable region (VH) that is identical to SEQ ID NO: 34.

8. The TIM-3 binding agent of claim 1, comprising a heavy chain variable region (VH) that is identical to SEQ ID NO: 34; and a light chain variable region (VL) that is identical to SEQ ID NO: 115.

9. The TIM-3 binding agent of claim 8, further comprising an IgG constant region.

10. The TIM-3 binding agent of claim 9, wherein the IgG constant region is an IgG4 constant region.

11. The TIM-3 binding agent of claim 1, wherein the TIM-3 binding agent is a monoclonal antibody or antigen-binding fragment thereof.

12. The TIM-3 binding agent of claim 1, wherein the TIM-3 binding agent inhibits TIM-3 signaling.

13. A pharmaceutical composition comprising the TIM-3-binding agent of claim 1 and a pharmaceutically acceptable carrier.

14. A T Cell Immunoglobulin and Mucin Domain-3 (TIM-3) binding agent that is an antibody comprising: an immunoglobulin light chain variable (VL) region comprising a light chain CDR1, a light chain CDR2, and a light chain CDR3 of SEQ ID NO:115; and an immunoglobulin heavy chain variable (VH) region comprising a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of SEQ ID NO:34.

15. The TIM-3 binding agent of claim 14, wherein the VL region comprises SEQ ID NO:115 and the VH region comprises SEQ ID NO:34.

16. The TIM-3 binding agent of claim 14 comprising: an immunoglobulin light chain variable (VL) region that is at least 90% identical to SEQ ID NO:115; and an immunoglobulin heavy chain variable (VH) region that is at least 90% identical to SEQ ID NO:34.

17. A pharmaceutical composition comprising the TIM-3 binding agent of claim 16 and a pharmaceutically acceptable carrier.

18. The TIM-3 binding agent of claim 16, for use in treating cancer.

19. The TIM-3 binding agent for use of claim 18, wherein the cancer is melanoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gall bladder cancer, laryngeal cancer, liver cancer, thyroid cancer, stomach cancer, salivary gland cancer, prostate cancer, pancreatic cancer, or Merkel cell carcinoma.

20. The TIM-3 binding agent for use of claim 18, wherein the TIM-3 binding agent is to be used in combination with a PD-1 binding agent.

21. The TIM-3 binding agent for use of claim 18, wherein the TIM-3 binding agent is to be used in combination with a LAG-3 binding agent.

22. The TIM-3 binding agent of claim 1 for use in treating cancer.

23. The TIM-3 binding agent for use of claim 22, wherein the cancer is melanoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gall bladder cancer, laryngeal cancer, liver cancer, thyroid cancer, stomach cancer, salivary gland cancer, prostate cancer, pancreatic cancer, or Merkel cell carcinoma.

24. The TIM-3 binding agent for use of claim 23, wherein the TIM-3 binding agent is to be used in combination with a PD-1 binding agent to the subject.

25. The TIM-3 binding agent for use of claim 23, wherein the TIM-3 binding agent is to be used in combination with a LAG-3 binding agent.